Explanation
of
Changes
to
Preamble
2­
Nitropropane:

See
revised
explanations
on
pp.
18
and
28.
We
have
expanded
on
summarizing
the
methodology
for
not
including
2­
nitropropane
in
the
Phase
II
risk
analysis.

Economic
Analyses:

See
revised
summary
numbers
on
pp.
4,
50,
and
the
table
on
p.
51.
The
table
on
p.
51
has
split
up
the
cost
savings
assumptions
for
the
expanded
de
minimis
exemption.

Section
Explanation
2­
Nitropropane
See
revised
explanations
on
pp.
18
and
28.
We
have
expanded
on
summarizing
the
methodology
for
not
including
2­
nitropropane
in
the
Phase
II
risk
analysis.

Economic
Analyses
See
revised
summary
numbers
on
pp.
4,
50,
and
the
table
on
p.
51.
The
table
on
p.
51
has
split
up
the
cost
savings
assumptions
for
the
expanded
de
minimis
exemption.
